Latest Breaking News On - Stefan riley - Page 2 : comparemela.com

Inozyme Pharma To Report Topline Data From Ongoing Phase 1/2 Trials Of INZ-701 In Adults With ABCC6 Deficiency And ENPP1 Deficiency On April 8, 2024

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April –– Phase 1 tr.

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 06, 2024 Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal.

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 –

Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 - Inozyme Pharma (NASDAQ:INZY)

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of